Twist Bioscience Completes $50 Million Financing to Fuel Advancement of Digital Storage in DNA and Drug Discovery

Download PDF SAN FRANCISCO, Calif. – April 2, 2018 — Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced the completion of a private placement of $50 million, bringing the total raised to $259 million since the company’s founding in 2013. “We have used our proprietary DNA... Read more

SGI-DNA Launches Automated Gene Libraries for Accelerated Drug Discovery and Development Research

LA JOLLA, CA — March 29, 2018 —SGI-DNA Inc., a wholly owned subsidiary of Synthetic Genomics Inc. (SGI), today launched BioXp™ Libraries for rapidly building diverse synthetic DNA fragments including degenerate, scanning, and variant libraries. For researchers working in drug discovery biology, structural biology, synthetic biology, and antibody and enzyme engineering, BioXp™ Libraries overcome several traditional... Read more

Exactis Innovation Selects Ion GeneStudio S5 Systems and Oncomine Assays to Drive Canadian Clinical Trial Studies

Exactis Innovation Selects Ion GeneStudio S5 Systems and Oncomine Assays to Drive Canadian Clinical Trial Studies Laboratory network standardizes on common NGS platform to efficiently profile patient samples across multiple cancer centers CARLSBAD, Calif., March 28, 2018 /PRNewswire/ — At risk cancer patients across Canada may now be able to have their tumors molecularly profiled... Read more

New Salmonella Multiplex PCR Solution for Simultaneous Detection of Three Salmonella Targets in One Rapid Test is Now Certified by AFNOR

New Salmonella Multiplex PCR Solution for Simultaneous Detection of Three Salmonella Targets in One Rapid Test is Now Certified by AFNOR Real-Time PCR workflow gains NF VALIDATION by AFNOR Certification for rapid and simultaneous detection of Salmonella species, Salmonella Typhimurium and Salmonella Enteritidis BASINGSTOKE, England, March 27, 2018 /PRNewswire/ — Laboratories performing tests for poultry producers... Read more

Pacific Biosciences Announces Ten-Unit Sequel System Order for Annoroad

MENLO PARK, Calif., March 27, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leader in long-read, high-resolution sequencing, today announced a purchase order for 10 PacBio® Sequel® Systems that are expected to be installed at Annoroad’s designated facility within the next several months, enhancing Annoroad’s large-scale genomic service capabilities across various fields... Read more

Horizon Discovery introduces whole human genome arrayed libraries to support CRISPR activation screening

Location: Cambridge 26/03/2018 First-to-market Edit-R CRISPRa arrayed crRNA libraries enable native gene overexpression for high-throughput gain-of-function screening Available as small gene families, bespoke collections, the druggable genome, or human genome-wide collection Cambridge, UK, 26 March 2018: Horizon Discovery (LSE: HZD) (“Horizon” or the “Company”), a global leader in the application of gene editing and gene modulation... Read more

Pacific Biosciences Prevails in Patent Eligibility Ruling Against Oxford Nanopore

MENLO PARK, Calif., March 22, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leader in long-read, high-resolution sequencing, today announced that Judge Leonard P. Stark of the U.S. District Court for the District of Delaware denied a motion to dismiss filed on December 14, 2017 by Oxford Nanopore Technologies, Inc., a wholly-owned... Read more

Bio-Techne Expands RNAscope® ISH Automation – Facilitating Drug Discovery and Development

New and updated assays increase application areas and improve performance MINNEAPOLIS, March 21, 2018 /PRNewswire/ — Bio-Techne has expanded the automation capabilities of its popular Advanced Cell Diagnostics (ACD)-branded RNAscope® in situ hybridization (ISH) technology with the launch of several new and updated assays. The developments increase both access to, and use of, RNAscope and improve overall robustness and ease-of-use.... Read more

Oxford Nanopore announces £100 million ($140M) fundraising from global investors

Tue 20th March 2018 Funding will support new manufacturing facility, commercial expansion, and development of new innovative products. Oxford, UK. Oxford Nanopore Technologies Ltd, the company behind the only portable real-time DNA/RNA sequencer, MinION, has raised £100M ($140M) in new investment. Funds were raised from global investors including GIC (Singapore), CCB International (CCBI, China), Hostplus (Australia),... Read more

Quanterix Corporation and DestiNA Genomics to Collaborate in Effort to Transform microRNA Biomarker Detection

Collaboration offers potential for PCR-free microRNA biomarker detection with high-specificity and ultra-sensitivity March 20, 2018 06:00 AM Pacific Daylight Time LEXINGTON, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced a collaboration with DestiNA Genomics, a manufacturer of patented reagents for nucleic acid detection.... Read more